Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Trial Profile

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; CNS cancer; Extranodal NK-T-cell lymphoma; Germ cell cancer; Haemangiosarcoma; Lymphoma; Myxoid liposarcoma; Neuroendocrine tumours; Ovarian cancer; Rhabdoid tumour; Sarcoma; Soft tissue sarcoma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms AcSe
  • Most Recent Events

    • 19 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 07 Jul 2023 Results (n=98) assessing the activity of pembrolizumab in rare and ultra-rare sarcomas published in the Lancet Oncology
    • 06 Feb 2023 Planned End Date changed from 1 Dec 2023 to 26 Dec 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top